IL294800A - Methods for treatment of cancer with an anti-tigit antagonist antibody - Google Patents
Methods for treatment of cancer with an anti-tigit antagonist antibodyInfo
- Publication number
- IL294800A IL294800A IL294800A IL29480022A IL294800A IL 294800 A IL294800 A IL 294800A IL 294800 A IL294800 A IL 294800A IL 29480022 A IL29480022 A IL 29480022A IL 294800 A IL294800 A IL 294800A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- dose
- weeks
- subjects
- population
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966448P | 2020-01-27 | 2020-01-27 | |
| US202062985822P | 2020-03-05 | 2020-03-05 | |
| US202062994272P | 2020-03-24 | 2020-03-24 | |
| PCT/US2020/024526 WO2021194481A1 (en) | 2020-03-24 | 2020-03-24 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| US202063059054P | 2020-07-30 | 2020-07-30 | |
| US202063059960P | 2020-07-31 | 2020-07-31 | |
| US202063074807P | 2020-09-04 | 2020-09-04 | |
| US202063074827P | 2020-09-04 | 2020-09-04 | |
| PCT/US2020/049415 WO2022050954A1 (en) | 2020-09-04 | 2020-09-04 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| US202063085890P | 2020-09-30 | 2020-09-30 | |
| US202063105198P | 2020-10-23 | 2020-10-23 | |
| US202063114517P | 2020-11-16 | 2020-11-16 | |
| US202063124693P | 2020-12-11 | 2020-12-11 | |
| US202063127109P | 2020-12-17 | 2020-12-17 | |
| PCT/US2021/015143 WO2021154761A1 (en) | 2020-01-27 | 2021-01-26 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294800A true IL294800A (en) | 2022-09-01 |
Family
ID=74626264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294800A IL294800A (en) | 2020-01-27 | 2021-01-26 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4096646A1 (https=) |
| JP (1) | JP2023511595A (https=) |
| KR (1) | KR20220133243A (https=) |
| CN (1) | CN115315256A (https=) |
| AU (1) | AU2021212662A1 (https=) |
| CA (1) | CA3165187A1 (https=) |
| IL (1) | IL294800A (https=) |
| MX (1) | MX2022009170A (https=) |
| TW (1) | TW202142230A (https=) |
| WO (1) | WO2021154761A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021293038A1 (en) * | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
| WO2023279092A2 (en) * | 2021-07-02 | 2023-01-05 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023010094A2 (en) * | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023018677A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s) |
| US20250064794A1 (en) * | 2021-08-10 | 2025-02-27 | Eisai R&D Management Co., Ltd. | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
| CN118103067A (zh) * | 2021-09-14 | 2024-05-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和化疗药的药物组合及其使用方法 |
| EP4403574A4 (en) * | 2021-09-15 | 2025-10-29 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PD-1-Specific Protein and Its Pharmaceutical Use |
| AU2022417501A1 (en) * | 2021-12-22 | 2024-07-04 | Genentech, Inc. | Clinical formulations of anti-tigit antibodies |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| WO2024130026A1 (en) * | 2022-12-16 | 2024-06-20 | Elevar Therapeutics, Inc. | Methods and compositions for treatment of subjects with hepatic impairments |
| MX2025006330A (es) * | 2022-12-23 | 2025-07-01 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer |
| WO2024206868A2 (en) * | 2023-03-31 | 2024-10-03 | Genentech, Inc. | Methods of treating tumors with anti-tigit antibodies |
| CN116716393A (zh) * | 2023-05-10 | 2023-09-08 | 首都医科大学附属北京儿童医院 | 用于检测caebv和im宿主差异甲基化基因的物质、试剂盒及其应用 |
| WO2024263195A1 (en) * | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025174933A1 (en) * | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
| CN118919054B (zh) * | 2024-07-12 | 2025-09-30 | 中国医学科学院肿瘤医院 | 基于聚类方法的特定疾病的复发概率的预测方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| CN104603620B (zh) | 2012-09-24 | 2018-02-23 | 文塔纳医疗系统公司 | 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法 |
| WO2015176033A1 (en) * | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| ES2835866T5 (es) | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| ES2789500T5 (es) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
-
2021
- 2021-01-26 TW TW110102913A patent/TW202142230A/zh unknown
- 2021-01-26 IL IL294800A patent/IL294800A/en unknown
- 2021-01-26 CN CN202180022830.2A patent/CN115315256A/zh active Pending
- 2021-01-26 AU AU2021212662A patent/AU2021212662A1/en active Pending
- 2021-01-26 MX MX2022009170A patent/MX2022009170A/es unknown
- 2021-01-26 WO PCT/US2021/015143 patent/WO2021154761A1/en not_active Ceased
- 2021-01-26 KR KR1020227029306A patent/KR20220133243A/ko active Pending
- 2021-01-26 CA CA3165187A patent/CA3165187A1/en active Pending
- 2021-01-26 JP JP2022545057A patent/JP2023511595A/ja active Pending
- 2021-01-26 EP EP21705841.1A patent/EP4096646A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022009170A (es) | 2022-08-17 |
| TW202142230A (zh) | 2021-11-16 |
| WO2021154761A1 (en) | 2021-08-05 |
| CA3165187A1 (en) | 2021-08-05 |
| JP2023511595A (ja) | 2023-03-20 |
| EP4096646A1 (en) | 2022-12-07 |
| CN115315256A (zh) | 2022-11-08 |
| KR20220133243A (ko) | 2022-10-04 |
| AU2021212662A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294800A (en) | Methods for treatment of cancer with an anti-tigit antagonist antibody | |
| JP2023511595A5 (https=) | ||
| JP2021514969A5 (https=) | ||
| WO2025037273A1 (en) | Anti-pd-l1 antibodies in combinations with one or more chemotherapy agents for treating endometrial cancer | |
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| Zhang et al. | Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives | |
| AU2019207812A1 (en) | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer | |
| JP2022513350A5 (https=) | ||
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| JP2023545521A5 (https=) | ||
| Maron et al. | Novel targeted therapies for esophagogastric cancer | |
| Roviello et al. | Maintenance in gastric cancer: New life for an old issue? | |
| JP2024516818A5 (https=) | ||
| JP2020507596A (ja) | 膀胱癌の抗ｐｄ−ｌ１抗体治療 | |
| JP2023531200A5 (https=) | ||
| JP2024071393A5 (https=) | ||
| Chen et al. | Application of immune checkpoint inhibitors in cancer | |
| JP2024536383A5 (https=) | ||
| JP2023551980A5 (https=) | ||
| Niho | Treatment of small cell lung cancer; advances and future prospects | |
| Lopez et al. | Current therapeutic landscape for advanced gastroesophageal cancers | |
| US20240317854A1 (en) | Methods for treating cancer with anti-ilt3 antibodies | |
| JP2024519450A5 (https=) | ||
| Simion et al. | HER2 positive breast Cancer Therapy-A Challenging and continuously moving Pathway–A narrative literature review: HER2+ BC therapy | |
| US20240042020A1 (en) | Anti-garp-tgf-beta1/pd-1 combination therapy |